The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Campaigns & Insights
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / October / The Evolution of Dry Eye Management
Anterior Segment Discussion Optometry

The Evolution of Dry Eye Management

Innovations shaping clinical practice

By Jacob Lang 10/21/2026 4 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Quiz
  • Poll
5 Key Takeaways
  • 1

    Personalized dry eye care begins by understanding patients’ symptoms, frustrations, and goals and correlating their experiences with clinical findings.

  • 2

    The SPEED survey and tests of tear osmolarity, MMP-9, tear volume, and tear breakup time can help characterize disease and guide treatment choices.

  • 3

    The author describes combining established therapies with newer options because dry eye is chronic and has no single curative therapy.

  • 4

    The therapies discussed include supplements, perfluorohexyloctane, acoltremon, canalicular gel, thermal gland expression, and intense pulsed light.

  • 5

    The author uses perfluorohexyloctane for evaporative dry eye or MGD, acoltremon for aqueous deficiency, and canalicular gel alone or with topical medications.

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: